Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease

Comparative Hepatology

Volumn 11, Issue 1, 2012, Pages

  Parkes, Julie ^a   Guha, Indra N ^b   Harris, Scott ^a   Rosenberg, William M C ^c,d   Roderick, Paul J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Alcoholic liver disease; Liver fibrosis; Serum markers; Systematic review

Indexed keywords

APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; HAPTOGLOBIN; HYALURONIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALCOHOL LIVER DISEASE; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; EMBASE; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDLINE; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84874357443     PISSN: None     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-11-5     Document Type: Review

References (39)

1. Breakwell C, Baker A, Griffiths C, Jackson G, Fegan G, Marshall D. Trends and geographical variations in alcohol-related deaths in the United Kingdom, 1991-2004. Health Stat Q 2007, (33):6-24.
2. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain, 1950 to 200226. Lancet 2006, 367(9511):645.
3. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La VC. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007, 46(5):827-839. 10.1016/j.jhep.2007.01.025, 17336419.
4. Room R. British livers and British alcohol policy1. Lancet 2006, 367(9504):10-11. 10.1016/S0140-6736(06)67901-4, 16399136.
5. Calling time; the nation's drinking as a major health issue 2004, London: Academy of Medical Sciences, 3577835, 23437054.
6. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97(10):2614-2618. 10.1111/j.1572-0241.2002.06038.x, 12385448.
7. Bedossa P, Dargere D, Paradis V. Sampling Variability of Liver Fibrosis in Chronic Hepatitis C. Hepatology 2003, 38(6):1449-1457.
8. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of varialbility in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-264. 10.1002/hep.20535, 15660389.
9. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002, 36(5 Suppl 1):S161-S172.
10. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44:462-474. 10.1016/j.jhep.2005.10.019, 16427156.
11. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease2. Gut 2006, 55(11):1650-1660. 10.1136/gut.2006.091454, 1860097, 17047111.
12. Francesco M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 2008, 5:95-106.
13. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis. C Alimentary Pharm Therap 2009, 30(6):557-576.
14. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001, 323(7305):157-162. 1120791, 11463691.
15. Gabrielli GB, Faccioli G, Casaril M, Capra F, Bonazzi L, Falezza G, et al. Procollagen III peptide and fibronectin in alcohol-related chronic liver disease: correlations with morphological features and biochemical tests. Clin Chim Acta 1989, 179:315-322. 10.1016/0009-8981(89)90094-6, 2714004.
16. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991, 100:1397-1402.
17. Li J, Rosman AS, Leo MA, Nagai Y, Lieber CS. Tissue inhibitor of matalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology 1994, 19(6):1418-1423. 10.1002/hep.1840190616, 8188171.
18. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis66. Gastroenterology 1997, 113(5):1609-1616. 10.1053/gast.1997.v113.pm9352863, 9352863.
19. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000, 12(9):989-993. 10.1097/00042737-200012090-00004, 11007134.
20. Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, et al. Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol 2000, 24(6-7):626-630.
21. Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Hartmann DJ, et al. Serum hyaluronan-a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000, 12(10):1121-1127. 10.1097/00042737-200012100-00009, 11057458.
22. Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002, 14(10):1133-1141. 10.1097/00042737-200210000-00015, 12362105.
23. Stickel F, Poeschl G, Schuppan D, Conradt C, Strenge-Hesse A, Fuchs FS, et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 2003, 15(9):01.
24. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713. 10.1053/j.gastro.2004.08.052, 15578508.
25. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3(2):167-174. 10.1016/S1542-3565(04)00625-1, 15704051.
26. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42(6):1373-1381. 10.1002/hep.20935, 16317693.
27. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006, 101(7):1500-1508. 10.1111/j.1572-0241.2006.00610.x, 16863553.
28. Nguyen-Khac E, Chatelain D, Tramer B, Decromecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
29. Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. alcoholism. Clin and Exp Res 2008, 32(6):1031-1039.
30. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prevot S, Ngo Y, Munteanu M, Balian A, Njike-Nakseu M, Perlemuter G, Poynard T. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009, 49:97-105. 10.1002/hep.22576, 19053048.
31. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49:7-18. 10.1373/49.1.7, 12507954.
32. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in CLD BMC. Gastroenterol 2007, 7:40.
33. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102(11):2589-2600. 10.1111/j.1572-0241.2007.01466.x, 17850410.
34. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46(3):912-921. 10.1002/hep.21835, 17705266.
35. Deaciuc IV, Spitzer JJ, Shellito JE, D'Souza NB. Acute alcohol administration to mice induces hepatic sinusoidal endothelial cell dysfunction. International Hepatology Communications 1994, 2(2):81-86.
36. Deaciuc IV, McDonough KH, Bagby GJ, Spitzer JJ. Alcohol consumption in rats potentiates the deleterious effect of Gram-negative sepsis on hepatic hyaluronan uptake. Alcohol Clin Exp Res 1993, 17:1002-1008. 10.1111/j.1530-0277.1993.tb05655.x, 8279658.
37. Ponomarenko Y, Leo MA, Kroll W, Lieber CS. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol & Alcoholism 2002, 37(3):252-255. 10.1093/alcalc/37.3.252, 3578795, 23437351.
38. Nouchi T, Worner TM, Sato S, Lieber CS. Serum procollagen type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease. Alcohol Clin Exp Res 1987 Jun, 11(3):287-91.
39. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages Clin. Chem 2007, 53(9):11615-22.